27 Participants Needed

CTL Therapy for Multivirus Infections

Age: < 65
Sex: Any
Trial Phase: Phase 1
Sponsor: Catherine Bollard
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

In this study, investigators are trying to see if infusion of T cells (called CTLs) will prevent or treat cytomegalovirus (CMV), Epstein Barr Virus (EBV) and adenovirus (AdV) reactivation or infection.Patients with blood cell cancer, other blood disease or a genetic disease may receive a stem cell transplant. After receiving transplant, they are at risk of infections until a new immune system to fight infections grows from the cord blood cells. In this study, investigators are trying to give special cells called T cells. These cells will try to fight viruses that can cause infection.Investigators will test to see if blood cells from donor that have been grown in a special way, can prevent patients from getting an infection. EBV, AdV and CMV are viruses that can cause serious life-threatening infections in patients who have weak immune systems after transplant.T lymphocytes can kill viral cells but normally there are not enough of them to kill all the virus infected cells after transplant. Some researcher have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person during a viral infection after a bone marrow transplant. Some of these studies have shown a positive therapeutic effect in patients receiving the CTLs after a viral infection in the post-transplant period.Investigators will grow these cells from donor in the laboratory in a way that will train them to recognize and remove viruses when the T cells are given after a transplant. Since most donors have previously been infected with EBV, CMV, and adenovirus, investigators are able to use their T cells that remember these viruses to grow the CTLs. However, they now also have a new way of growing CTLs from donors who have not been infected with CMV.

Who Is on the Research Team?

CB

Catherine Bollard, MD

Principal Investigator

Children's National Research Institute

Are You a Good Fit for This Trial?

This trial is for patients with blood cancers or genetic diseases who've had a stem cell transplant within the last year. They should be at risk of, or currently fighting, CMV, EBV, or Adenovirus infections. Participants need to have stable vital signs and organ function and not be on high doses of steroids. Pregnant women and those with uncontrolled cancer relapse or other severe infections cannot join.

Inclusion Criteria

I am receiving early treatment for infections, including cases with both reactivation and controlled infections.
Bilirubin <2x, AST <3x, Serum creatinine <2x upper limit of normal, Hgb >8.0
Available multivirus-specific cytotoxic T lymphocytes
See 10 more

Exclusion Criteria

I cannot reduce my steroid dose to less than or equal to 0.5 mg/kg/day.
I received a donor lymphocyte infusion in the last 28 days.
My cancer is currently growing or spreading.
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive multivirus-directed cytotoxic T lymphocytes (CTL) infusions targeting CMV, EBV, and adenovirus

45 days
3 visits (in-person) for dose administration

Follow-up

Participants are monitored for safety and effectiveness after CTL infusion

3 months

What Are the Treatments Tested in This Trial?

Interventions

  • Allogeneic Multivirus-Directed CTL
Trial Overview The study tests whether T cells (CTLs) grown from donors can prevent or treat viral infections like CMV, EBV, and Adenovirus in patients post-transplant. CTLs are trained in the lab to fight these viruses and then infused into patients to boost their immune response against potential life-threatening infections.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: CTL for CMV seropositive donorsExperimental Treatment1 Intervention
CTL for CMV seropositive donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors- three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
Group II: CTL for CMV naïve donorsExperimental Treatment1 Intervention
CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton)for CMV naïve donors-each group will undergo an identical dose escalation. Three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Catherine Bollard

Lead Sponsor

Trials
13
Recruited
290+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security